The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report 2024
Synopsis
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Report Scope
The B-Cell Maturation Antigen (BCMA) Targeted Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the B-Cell Maturation Antigen (BCMA) Targeted Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Segment by Type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Segment by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global B-Cell Maturation Antigen (BCMA) Targeted Therapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for B-Cell Maturation Antigen (BCMA) Targeted Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Report Scope
The B-Cell Maturation Antigen (BCMA) Targeted Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the B-Cell Maturation Antigen (BCMA) Targeted Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Segment by Type
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Segment by Application
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Bispecific Antibodies
1.2.3 Antibody Drug Conjugates
1.2.4 Chimeric Antigen Receptor T-Cells
1.3 Market by Application
1.3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Perspective (2019-2030)
2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Growth Trends by Region
2.2.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Region (2019-2024)
2.2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Region (2025-2030)
2.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Dynamics
2.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Trends
2.3.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
2.3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Challenges
2.3.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue
3.1.1 Global Top B-Cell Maturation Antigen (BCMA) Targeted Therapies Players by Revenue (2019-2024)
3.1.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Players (2019-2024)
3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue
3.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio
3.4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue in 2023
3.5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Key Players Head office and Area Served
3.6 Key Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Product Solution and Service
3.7 Date of Enter into B-Cell Maturation Antigen (BCMA) Targeted Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Type
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Type (2019-2024)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Type (2025-2030)
5 B-Cell Maturation Antigen (BCMA) Targeted Therapies Breakdown Data by Application
5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Historic Market Size by Application (2019-2024)
5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
6.4 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
7.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2019-2024)
8.4 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
9.2 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
9.4 Latin America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size (2019-2030)
10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2019-2024)
10.4 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Transposagen Biopharmaceuticals
11.1.1 Transposagen Biopharmaceuticals Company Detail
11.1.2 Transposagen Biopharmaceuticals Business Overview
11.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.1.4 Transposagen Biopharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.1.5 Transposagen Biopharmaceuticals Recent Development
11.2 Sutro Biopharma
11.2.1 Sutro Biopharma Company Detail
11.2.2 Sutro Biopharma Business Overview
11.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.2.4 Sutro Biopharma Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.2.5 Sutro Biopharma Recent Development
11.3 Malin Corporation
11.3.1 Malin Corporation Company Detail
11.3.2 Malin Corporation Business Overview
11.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.3.4 Malin Corporation Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.3.5 Malin Corporation Recent Development
11.4 Eureka Therapeutics
11.4.1 Eureka Therapeutics Company Detail
11.4.2 Eureka Therapeutics Business Overview
11.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.4.4 Eureka Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.4.5 Eureka Therapeutics Recent Development
11.5 firstVentury Equity
11.5.1 firstVentury Equity Company Detail
11.5.2 firstVentury Equity Business Overview
11.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.5.4 firstVentury Equity Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.5.5 firstVentury Equity Recent Development
11.6 Five Prime Therapeutics
11.6.1 Five Prime Therapeutics Company Detail
11.6.2 Five Prime Therapeutics Business Overview
11.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.6.4 Five Prime Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.6.5 Five Prime Therapeutics Recent Development
11.7 Credit Suisse Securities
11.7.1 Credit Suisse Securities Company Detail
11.7.2 Credit Suisse Securities Business Overview
11.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.7.4 Credit Suisse Securities Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.7.5 Credit Suisse Securities Recent Development
11.8 Dana-Farber Cancer Institute
11.8.1 Dana-Farber Cancer Institute Company Detail
11.8.2 Dana-Farber Cancer Institute Business Overview
11.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.8.4 Dana-Farber Cancer Institute Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.8.5 Dana-Farber Cancer Institute Recent Development
11.9 Deerfield Partners
11.9.1 Deerfield Partners Company Detail
11.9.2 Deerfield Partners Business Overview
11.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.9.4 Deerfield Partners Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.9.5 Deerfield Partners Recent Development
11.10 Onyx Pharmaceuticals
11.10.1 Onyx Pharmaceuticals Company Detail
11.10.2 Onyx Pharmaceuticals Business Overview
11.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.10.4 Onyx Pharmaceuticals Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.10.5 Onyx Pharmaceuticals Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Detail
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Introduction
11.11.4 Juno Therapeutics Revenue in B-Cell Maturation Antigen (BCMA) Targeted Therapies Business (2019-2024)
11.11.5 Juno Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
